Clinical trials: Dementia With Lewy Bodies
Dementia With Lewy Bodies
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
This 6-month extension study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) in subjects with Dementia with Lewy bodies (DLB) who have participated in the double-blind…
- Trial name
- NCT02928445
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 56 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Axovant Sciences Ltd.
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with…
- Trial name
- CLIN-011 (NCT04739423)
- Where
- 7 sites in Australia, New Zealand and 1 more
- Volunteers
- 41 people
- Sponsor
- CuraSen Therapeutics, Inc.
Dementia-related Psychosis
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
The purpose of this study is to evaluate the efficacy of pimavanserin compared to placebo in preventing relapse of psychotic symptoms in subjects with dementia-related psychosis who responded to 12 weeks of open label…
- Trial name
- NCT03325556
- Testing
- Pimavanserin 34 mg, Pimavanserin 20 mg
- Where
- 83 sites in United States, Bulgaria and 11 more
- Volunteers
- 392 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Alzheimer's Disease, Lewy Body Dementia
Pulsed Electromagnetic Field Treatment With Dementia Patients
An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Conditions
- Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
- Trial name
- NCT06862557
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Herrick Medical LLC
Dementia, Lewy Body, Lewy Body Disease
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
The purpose of this study is to confirm the efficacy of Aricept in patients with dementia with Lewy bodies (DLB).
- Trial name
- NCT02345213
- Testing
- E2020
- Where
- Japan
- Volunteers
- 160 people
- Sponsor
- Eisai Co., Ltd.
Parkinson Disease (PD), Lewy Body Dementia (LBD)
18F-mFBG Cardiac Uptake With Lewy Body Dementia
This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation.
- Trial name
- IRP101-231 (NCT07176286)
- Testing
- 18F-MFBG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Mild Cognitive Impairment, Mild Dementia
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04148391
- Testing
- NYX-458
- Where
- 26 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aptinyx
Lewy Body Dementia, Non-DLB Dementia
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical…
- Conditions
- Lewy Body Dementia, Non-DLB Dementia, Alzheimer's, Vascular Dementia
- Trial name
- NCT00209456
- Testing
- DatSCAN
- Where
- Germany
- Volunteers
- 326 people
- Sponsor
- GE Healthcare
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Lewy Body Disease
Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies
TRIAL SUMMARY: This is an open-label, 24-week, investigator initiated study to evaluate the safety and efficacy of galantamine (16 8 to 24 mg/day; flexible dosing) in the treatment of Dementia with Lewy bodies.
- Trial name
- NCT00230997
- Testing
- Galantamine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Neurological Research Center
Lewy Body Dementia Psychosis
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
- Trial name
- NCT07095465
- Testing
- ACP-204
- Where
- 32 sites in United States, Bulgaria and 4 more
- Volunteers
- 126 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB)
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Progressive supranuclear palsy (PSP), mild cognitive impairment with Lewy bodies (MCI-LB), and Dementia with Lewy Bodies (DLB) are severe neurodegenerative diseases that cause significant motor impairment impacting daily…
- Conditions
- Progressive Supranuclear Palsy(PSP), Dementia With Lewy Bodies (DLB), PSP, Lewy Body Dementia (LBD)
- Trial name
- NCT07240805
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Alzheimer Disease, Alzheimer Dementia
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and…
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease
- Trial name
- ACIST (NCT03724136)
- Testing
- Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 100 people
- Sponsor
- MD Stem Cells
Alzheimer Disease, Mild Cognitive Impairment
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular
- Trial name
- RHAPSODY (NCT04939818)
- Where
- 2 sites in United Kingdom
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Dementias With Lewy Bodies
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
The primary objective of the study is to achieve mass balance recovery of [14C]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
- Trial name
- NCT04023877
- Testing
- E2027
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Mild Cognitive Impairment, Dementia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
This retrospective study is a more extensive, confirmatory analysis of the cognitive and functional outcomes initially seen in 2 groups of MCI/dementia patients in Springfield, MA and compares specialized dementia care and a…
- Conditions
- Mild Cognitive Impairment, Dementia, Hypoxia, Hyperhomocysteinemia
- Trial name
- NCT02860338
- Volunteers
- 900 people
- Sponsor
- Clionsky Neuro Systems Inc.
Parkinson's Disease Dementia, Dementia With Lewy Bodies
Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies
The purpose of this exploratory study is to determine whether memantine can provide benefits on clinical symptoms in patients with Parkinson's Disease Dementia or Dementia with Lewy Bodies.
- Trial name
- NCT00855686
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 199 people
- Sponsor
- H. Lundbeck A/S
Dementia With Lewy Bodies
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB.
- Trial name
- NCT05869669
- Testing
- Neflamapimod
- Where
- 40 sites in United States, Netherlands and 1 more
- Volunteers
- 159 people
- Sponsor
- EIP Pharma Inc
Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
- Trial name
- NCT02669433
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 65 sites in United States, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Axovant Sciences Ltd.